← Back to Search

[18F]-Fluorodeoxyglucose for Tumors

Phase 3
Waitlist Available
Led By Daniel P Levin, BSc,MD,FRCPC
Research Sponsored by University of Manitoba
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up three years
Awards & highlights
No Placebo-Only Group
Pivotal Trial

Summary

This clinical trial is being conducted to study the use of a radioactive glucose tracer as an imaging test \[Positron Emission Tomography (PET)scan\] in adults who have or are suspected of having cancer and in another group of adults to assess for neurologic conditions.

Eligible Conditions
  • Tumors

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~three years
This trial's timeline: 3 weeks for screening, Varies for treatment, and three years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
To confirm the diagnostic effectiveness of 18F-Fluorodeoxyglucose(FDG) as compared to the gold standard of histopathological diagnosis.

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

1Treatment groups
Experimental Treatment
Group I: [18F]-FluorodeoxyglucoseExperimental Treatment1 Intervention
Scanning Procedure: Non-diagnostic Computed Tomography (CT) scan followed by a Diagnostic Positron Emission Tomography (PET) scan.

Find a Location

Who is running the clinical trial?

Winnipeg Regional Health AuthorityOTHER
8 Previous Clinical Trials
940 Total Patients Enrolled
University of ManitobaLead Sponsor
618 Previous Clinical Trials
205,709 Total Patients Enrolled
Daniel P Levin, BSc,MD,FRCPCPrincipal InvestigatorWinnipeg Regional Health Authority
~65 spots leftby Nov 2025